Evidence map›Paper›PMID 33869021›Full record

ArticleFrontiers in oncology2021

Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs.

Wei Guo, Xingyuan Ma, Yunhui Fu, Chang Liu, Qiuli Liu, Fabiao Hu, Hui Miao, Tong Zhang, Yuping Liu, Myong Hun Han and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Wei GuoState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Xingyuan MaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Yunhui FuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Chang LiuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Qiuli LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Fabiao HuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Hui MiaoState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Tong ZhangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Yuping LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Myong Hun HanState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Fang YouDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, Singapore.
Yi YangDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, Singapore.
Wenyun ZhengShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
East China University of Science and Technology · CNNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survivin as a member of the inhibitor of apoptosis proteins (IAPs) family is undetectable in normal cells, but highly expressed in cancer cells and cancer stem cells (CSCs) which makes it an attractive target in cancer therapy. Survivin dominant negative mutants have been reported as competitive inhibitors of endogenous survivin protein in cancer cells. However, there is a lack of systematic comparative studies on which mutants have stronger effect on promoting apoptosis in cancer cells, which will hinder the development of novel anti-cancer drugs. Here, based on the previous study of survivin and its analysis of the relationship between structure and function, we designed and constructed a series of different amino acid mutants from survivin (TmSm34, TmSm48, TmSm84, TmSm34/48, TmSm34/84, and TmSm34/48/84) fused cell-permeable peptide TATm at the N-terminus, and a dominant negative mutant TmSm34/84 with stronger pro-apoptotic activity was selected and evaluated systematically

Indexed as

A549 cells and CSCsdiscovering and characterizingsensitizing chemotherapeutic drugsstronger pro-apoptotic activitysurvivin mutant (TmSm34/84)

Identifiers

PMID33869021
PMCPMC8045750
OpenAlexW3139888860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.